Predictive biomarkers in advance of a companion drug: ahead of their time?
J Natl Compr Canc Netw., Mar;10(3):303-9 (2012)
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.
Oncologist., 15 Suppl 4:5-13 (2010)
Adjuvant treatment of colon cancer: what is next?
Curr Opin Oncol., Jul;23(4):403-9 (2011)
Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
Clin Colorectal Cancer., Jun;10(2):73-80 (2011)
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Cancer Chemother. Pharmacol., Nov;66(6):1051-7 (2010)
Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
Arch Surg., Mar;145(3):276-80 (2010)
Drug development in advanced colorectal cancer: challenges and opportunities.
Curr Oncol Rep., May;11(3):175-85 (2009)
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Cancer Invest., Feb;26(1):47-52 (2008)
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Invest New Drugs., Oct;26(5):463-71 (2008)
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
J. Clin. Oncol., Jan;24(3):379-85 (2006)
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
Clin Colorectal Cancer., Nov;5(4):292-4 (2005)
Targeted therapy in colorectal cancer.
Clin Adv Hematol Oncol., Feb;4(2):124-32 (2006)
Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver.
Clin Imaging., 31(1):6-10 (2007)
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Int. J. Radiat. Oncol. Biol. Phys., Jul;68(3):809-16 (2007)
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
Clin Colorectal Cancer., May;6(7):536-8 (2007)
Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
Surg. Oncol. Clin. N. Am., Jul;16(3):639-51, x (2007)
Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
Clin. Cancer Res., Mar;11(5):1791-7 (2005)
Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
Cancer., Jun;103(12):2435-46 (2005)
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
Br. J. Cancer., Jul;93(2):195-9 (2005)
Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
J Natl Compr Canc Netw., Sep;2 Suppl 2:S74-84 (2004)